مجلة الدراسات التربوية والعلمية - كلية التربية - الجامعة العراقية
العدد الرابع والعشرون - المجلد الخامس - علوم الحياة - كانون أول 2024 م
doi.org/10.52866/esj.2024.05.24.28

The Role of SDF-1.CXCR4 Axis in Colon Cancer Progression: A Comprehensive Review

Suhad Dali Al-Ukadi ، Dr.Hazima Mossa Al-Aabassi
University of Baghdad - College of Education
for Pure Sciences Ibn Al-Haitham - Department of Biology

Abstruct:

Study on the role of the SDF1-CXCR4 axis in colon cancer development highlights its critical importance in global health, demonstrating how cancer development is influenced by a combination of genetic and environmental factors. It delves into the role of SDF1 and CXCR4 proteins in controlling cellular processes, considering the SDF1-CXCR4 axis as a critical signaling pathway that affects cell movement and angiogenesis and how disruptions in this axis contribute to the development of aggressive tumor features and resistance to treatment, making it a potential marker for diagnosis and a target for treatment. Deciphering the prevailing molecular dynamics and providing insights into personalized treatment strategies, emphasizing the shift towards personalized medicine. It seeks to pioneer precision medicine tactics and create new treatments for colon cancer by exploring the complex interactions between the SDF1-CXCR4 axis and diverse molecular pathways..

Key word: SDF-1 ; CXCR4 ; Colon Cancer ; Tumer .

دور محور SDF-1.CXC4 في تطور سرطان القولون : مراجعة شاملة

سهاد دلي العكيدي ، أ.د حازمة موسى العباسي
جامعة بغداد / كلية التربية للعلوم الصرفة ابن الهيثم - قسم علوم الحياة

مستخلص:

تسلط الدراسة حول دور محور SDF1-CXCR4 في تطور سرطان القولون الضوء على أهميته الحاسمة في الصحة العالمية، مما يوضح كيف يتأثر تطور السرطان بمزيج من العوامل الوراثية والبيئية. إنه يتعمق في دور بروتينات SDF1 و CXCR4 في التحكم في العمليات الخلوية، مع الأخذ في الاعتبار محور SDF1-CXCR4 كمسار إشارات حاسم يؤثر على حركية الخلية وتولد الأوعية وكيف تساهم الاضطرابات في هذا المحور في تطوير ميزات الورم العدوانية ومقاومة العلاج. وهذا يجعلها علامة محتملة للتشخيص وهدفا للعلاج. وفك رموز الديناميكيات الجزيئية السائدة وتقديم نظرة ثاقبة لاستراتيجيات العلاج الشخصية، مع التركيز على التحول نحو الطب الشخصي. وهو يسعى إلى الريادة في تكتيكات الطب الدقيق وإنشاء علاجات جديدة لسرطان القولون من خلال استكشاف التفاعلات المعقدة بين محور SDF1-CXCR4 والمسارات الجزيئية المتنوعة.

Introduction

Colon cancer, also known as colorectal cancer, represents a significant global health burden and remains a leading cause of cancer-related mortality worldwide. The intricate interplay between genetic and environmental factors contributes to the complex pathogenesis of colon cancer, encompassing multifaceted molecular alterations that drive tumor initiation, progression, and metastasis. In recent years, a growing body of evidence has highlighted the pivotal role of the Stromal Cell-Derived Factor 1 (SDF1) and its receptor, C-X-C chemokine receptor type 4 (CXCR4), in modulating key cellular processes implicated in colon cancer development and metastatic dissemination.(24)

The SDF1-CXCR4 axis, a critical signaling pathway involved in cell migration, proliferation, and angiogenesis, has emerged as a key regulator of tumor microenvironment dynamics and immune cell infiltration in the context of colon cancer. Dysregulation of the SDF1-CXCR4 axis has been implicated in the acquisition of aggressive tumor phenotypes, therapeutic resistance, and poor clinical outcomes, underscoring its potential as a valuable prognostic indicator and therapeutic target in the management of colon cancer.(44)

This comprehensive review aims to elucidate the intricate molecular mechanisms underlying the role of the SDF1-CXCR4 axis in colon cancer progression, with a particular focus on its impact on tumor cell proliferation, angiogenesis, metastasis, and immune evasion. Additionally, this review will provide insights into the translational implications of targeting the SDF1-CXCR4 axis in colon cancer management, emphasizing the potential for personalized therapeutic approaches that leverage the unique molecular characteristics of individual tumors. By delving into the complex interactions between the SDF1-CXCR4 axis and other key molecular pathways, this review seeks to contribute to the development of innovative precision medicine strategies that hold promise for improving patient outcomes and advancing the field of colon cancer therapeutics.(13)

1. The SDF1-CXCR4 Axis: Molecular Signaling Pathway

The SDF1-CXCR4 axis plays a crucial role in modulating diverse

cellular processes through a complex molecular signaling pathway. Stromal Cell-Derived Factor 1 (SDF1), also known as CXCL12, serves as the ligand for C-X-C chemokine receptor type 4 (CXCR4), a G-protein-coupled receptor located on the cell membrane. The binding of SDF1 to CXCR4 initiates a cascade of intracellular signaling events, leading to the activation of various downstream signaling pathways that contribute to the regulation of cell survival, proliferation, and migration.(8).

Upon ligand binding, CXCR4 undergoes conformational changes, leading to the activation of heterotrimeric G proteins, which subsequently activate downstream effectors such as phospholipase C (PLC), phosphoinositide 3-kinase (PI3K), and mitogen-activated protein kinase (MAPK). Activation of the PI3K pathway results in the phosphorylation of AKT, thereby promoting cell survival and proliferation. Similarly, activation of the MAPK pathway triggers the phosphorylation of extracellular signal-regulated kinases (ERKs), leading to the regulation of gene expression involved in cell proliferation and differentiation.(22)

Furthermore, the SDF1-CXCR4 axis influences the reorganization of the actin cytoskeleton, facilitating cell migration and invasion through the activation of small GTPases such as RhoA and Rac. Additionally, the SDF1-CXCR4 signaling pathway has been implicated in the regulation of angiogenesis and the recruitment of immune cells to the tumor microenvironment, thereby influencing the tumor immune response.(45)

Understanding the intricate molecular signaling pathway of the SDF1-CXCR4 axis is crucial for elucidating its functional roles in various physiological and pathological processes, including cancer progression, metastasis, and immune modulation.(2).

2. SDF1 (CXCL12): Chemokine Signaling in Physiological Contexts

Stromal cell-derived factor 1 (SDF1), also known as C-X-C motif chemokine 12 (CXCL12), functions as a pivotal chemokine involved in diverse physiological processes beyond its role in cancer progression. In normal physiology, SDF1 serves as a crucial regulator of immune cell trafficking and hematopoietic stem cell homing, contributing to the maintenance of tissue homeostasis and im-

mune surveillance. It plays a central role in embryonic development, participating in organogenesis, neurogenesis, and angiogenesis.(37).

Moreover, SDF1-mediated signaling is essential for the mobilization and recruitment of progenitor cells, contributing to tissue repair and regeneration in response to injury. The dynamic interplay between SDF1 and its receptors, including CXCR4 and CXCR7, regulates various cellular functions, such as cell adhesion, migration, and differentiation, in a context-dependent manner. The balance between SDF1 gradients and receptor expression levels governs the precise orchestration of cell trafficking and cell fate determination during development and tissue homeostasis.(4).

Furthermore, SDF1 signaling is implicated in the modulation of cardiovascular function, including angiogenesis and cardiac repair following myocardial infarction. Understanding the multifaceted roles of SDF1 (CXCL12) in physiological contexts is crucial for elucidating its diverse functions in tissue development, immune regulation, and regenerative processes, thus providing valuable insights into the potential implications of targeting the SDF1-CXCR4 axis in the context of therapeutic interventions beyond oncology.(17).

3. CXCR4: Receptor Activation and Downstream Signaling Cascades

C-X-C chemokine receptor type 4 (CXCR4), a key G-protein-coupled receptor, plays a crucial role in transducing signals initiated by its ligand, stromal cell-derived factor 1 (SDF1 or CXCL12), to mediate various cellular processes. Upon ligand binding, CXCR4 undergoes conformational changes, leading to the activation of heterotrimeric G proteins, primarily Gαi (Guanine nucleotide-binding protein G(i) subunit alpha), which subsequently dissociates into Gαi and Gβγ subunits. The activated Gαi subunit inhibits adenylyl cyclase, leading to decreased cAMP levels and subsequent inhibition of protein kinase A (PKA) signaling.(25)

Furthermore, the Gβγ subunit activates phospholipase C (PLC), leading to the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 induces the release of calcium ions from intracellular stores, triggering various down-

stream signaling cascades, while DAG activates protein kinase C (PKC), leading to the phosphorylation of target proteins involved in cell survival, proliferation, and migration.(6).

Additionally, CXCR4 activation stimulates the recruitment and activation of focal adhesion kinase (FAK) and Src kinase, promoting the reorganization of the actin cytoskeleton and facilitating cell migration and invasion. The activation of mitogen-activated protein kinase (MAPK) signaling pathways, including the extracellular signal-regulated kinase (ERK) pathway, c-Jun N-terminal kinase (JNK) pathway, and p38 MAPK pathway, further regulates gene expression involved in cell proliferation, survival, and differentiation.(10)

Elucidating the intricate signaling cascades downstream of CXCR4 activation is crucial for understanding its functional roles in various physiological and pathological processes, including cancer progression, metastasis, and immune modulation.(54).

4. Expression and Regulation of SDF1-CXCR4 in Colon Cancer

The dysregulated expression of the Stromal Cell-Derived Factor 1 (SDF1) and its cognate receptor, C-X-C chemokine receptor type 4 (CXCR4), plays a critical role in the pathogenesis of colon cancer. Aberrant upregulation of CXCR4 is frequently observed in various stages of colon cancer, correlating with disease progression, metastatic spread, and poor clinical outcomes. Elevated levels of CXCR4 are associated with enhanced tumor cell proliferation, increased angiogenesis, and augmented invasive potential, highlighting its significance as a potential prognostic biomarker and therapeutic target in colon cancer management.(1)

Moreover, the dysregulation of SDF1 expression within the tumor microenvironment contributes to the establishment of a pro-tumorigenic niche that fosters tumor growth and metastatic colonization. The interplay between SDF1 and CXCR4 influences the recruitment of cancer-associated fibroblasts, immune cells, and endothelial progenitor cells, promoting tumor-stromal interactions and facilitating tumor progression. Additionally, the modulation of SDF1-CXCR4 signaling by various regulatory factors, including microRNAs, transcription factors, and epigenetic modifiers, further contributes to the complex regu-

latory network governing colon cancer pathogenesis.(29)

Understanding the intricate mechanisms underlying the expression and regulation of the SDF1-CXCR4 axis in colon cancer is crucial for identifying novel therapeutic targets and developing tailored treatment strategies that effectively disrupt key signaling pathways driving tumor growth and metastasis. Integrating these insights into the development of precision medicine approaches holds promise for improving patient outcomes and advancing the field of colon cancer therapeutics.(13)

4.1. Upregulation of CXCR4: Implications for Tumor Growth

The upregulation of C-X-C chemokine receptor type 4 (CXCR4) in colon cancer is associated with significant implications for tumor growth and progression. Elevated CXCR4 expression contributes to enhanced tumor cell proliferation, survival, and evasion of apoptotic signals, thereby promoting tumor growth and aggressiveness. The overexpression of CXCR4 is frequently correlated with increased metastatic potential and is indicative of poor clinical prognosis in colon cancer patients.(22)

The binding of Stromal Cell-Derived Factor 1 (SDF1) to CXCR4 triggers downstream signaling cascades that promote cell cycle progression, angiogenesis, and resistance to apoptotic stimuli, fostering an environment conducive to uncontrolled tumor cell proliferation and survival. The dysregulated CXCR4-mediated signaling network further influences the recruitment of tumor-associated stromal cells, such as cancer-associated fibroblasts and endothelial progenitor cells, fostering the establishment of a pro-tumorigenic microenvironment that sustains tumor growth and metastatic dissemination.(36)

Moreover, CXCR4 upregulation has been implicated in the induction of epithelial-mesenchymal transition (EMT), a key process associated with increased tumor invasiveness and metastatic spread. Through the activation of various downstream effectors, including the PI3K/AKT and MAPK/ERK signaling pathways, CXCR4 contributes to the acquisition of a more aggressive phenotype characterized by increased migratory and invasive potential.(19)

The implications of CXCR4 upregulation for tumor growth provides

valuable insights into the mechanistic underpinnings of colon cancer progression, highlighting the potential of CXCR4 as a promising therapeutic target for the development of tailored treatment strategies aimed at mitigating tumor growth and improving patient outcomes.(59)

4.2. Disregulation of SDF1: Influence on Tumor Microenvironment

The dysregulation of Stromal Cell-Derived Factor 1 (SDF1) within the tumor microenvironment significantly impacts the intricate interplay between tumor cells and the surrounding stromal components, exerting profound effects on various aspects of colon cancer progression. Aberrant SDF1 expression contributes to the establishment of a pro-tumorigenic niche characterized by enhanced angiogenesis, immune suppression, and altered extracellular matrix remodeling, fostering a microenvironment conducive to tumor growth and metastasis.(9)

The dysregulated SDF1 gradient within the tumor microenvironment influences the recruitment and infiltration of CXCR4-expressing immune cells, such as regulatory T cells and tumor-associated macrophages, promoting an immunosuppressive milieu that inhibits effective anti-tumor immune responses. Furthermore, the interaction between SDF1 and its receptors stimulates the secretion of pro-angiogenic factors, facilitating the formation of an extensive network of tumor-associated blood vessels that sustain nutrient supply and oxygenation, promoting tumor growth and metastatic dissemination.(31)

Moreover, dysregulated SDF1 signaling contributes to the remodeling of the extracellular matrix, promoting tumor cell invasion and facilitating the establishment of a pre-metastatic niche that supports the colonization of distant organs. The dynamic interplay between dysregulated SDF1 and the tumor microenvironment influences various signaling pathways that regulate cell adhesion, migration, and survival, thereby shaping the aggressive phenotype of colon cancer and impacting disease progression.(50)

The influence of disregulated SDF1 on the tumor microenvironment provides valuable insights into the complex intercellular interactions driving colon cancer pathogenesis, highlighting the potential of SDF1 as a key therapeutic target for the development of innovative treatment strategies

aimed at modulating the tumor microenvironment and improving patient outcomes.(20).

5. Functional Roles of SDF1-CXCR4 in Colon Cancer

The SDF1-CXCR4 axis plays diverse functional roles in the intricate landscape of colon cancer, encompassing key processes that contribute to tumor growth, angiogenesis, metastasis, and immune modulation. The interplay between Stromal Cell-Derived Factor 1 (SDF1) and its receptor, C-X-C chemokine receptor type 4 (CXCR4), orchestrates critical signaling pathways that regulate tumor cell proliferation, survival, and invasion, thereby driving the aggressive phenotype of colon cancer and influencing disease progression.(45)

SDF1-mediated activation of CXCR4 promotes tumor cell proliferation and survival through the activation of pro-survival signaling pathways, including the PI3K/AKT and MAPK/ERK pathways. Additionally, the SDF1-CXCR4 axis contributes to the induction of angiogenesis, facilitating the formation of tumor-associated blood vessels through the activation of VEGF-mediated signaling cascades, thereby supporting nutrient supply and oxygenation essential for tumor growth and metastatic dissemination.(30)

Furthermore, the SDF1-CXCR4 axis influences tumor cell invasion and metastasis through its regulatory effects on epithelial-mesenchymal transition (EMT), facilitating the acquisition of a more aggressive and invasive phenotype. The dysregulated SDF1-CXCR4 signaling network also impacts the immune landscape of the tumor microenvironment, modulating the recruitment and activity of immune cells and promoting immune evasion, thereby facilitating tumor immune escape and resistance to immunotherapy.(23)

The multifaceted functional roles of the SDF1-CXCR4 axis in colon cancer provides valuable insights into the complex interplay between tumor cells and the surrounding microenvironment, underscoring the potential of targeting SDF1-CXCR4 as a promising therapeutic strategy for mitigating tumor progression and improving patient outcomes.(55)

5.1 Tumor Cell Proliferation and Survival

The SDF1-CXCR4 axis exerts a significant influence on tumor cell pro-

liferation and survival in colon cancer, contributing to the acquisition of aggressive tumor phenotypes and the development of therapeutic resistance. Activation of the SDF1-CXCR4 signaling cascade promotes tumor cell proliferation by stimulating the activation of key signaling pathways, including the PI3K/AKT and MAPK/ERK pathways. This activation leads to the upregulation of anti-apoptotic proteins and the promotion of cell cycle progression, thereby fostering uncontrolled tumor cell proliferation and survival.(16)

The dysregulated SDF1-CXCR4 axis facilitates the evasion of apoptotic signals and enhances the resistance of tumor cells to various forms of therapeutic intervention. Through the activation of pro-survival signaling cascades, SDF1-CXCR4 signaling promotes the expression of anti-apoptotic proteins, such as Bcl-2 and survivin, while simultaneously suppressing the activity of pro-apoptotic factors, thereby conferring a survival advantage to tumor cells in the hostile tumor microenvironment.(14)

Furthermore, the SDF1-CXCR4 axis plays a crucial role in the maintenance of cancer stem cell populations, contributing to self-renewal and tumor-initiating potential. The activation of CXCR4-mediated signaling pathways sustains the stemness of cancer stem cells, promoting tumor growth, metastatic colonization, and therapeutic resistance.(37)

Understanding the intricate interplay between the SDF1-CXCR4 axis and tumor cell proliferation and survival provides valuable insights into the molecular mechanisms underpinning colon cancer progression, highlighting the potential of targeting this axis as a promising therapeutic strategy aimed at mitigating tumor cell proliferation, enhancing treatment efficacy, and improving patient outcomes.(40)

5.2. Angiogenesis and Neovascularization

The SDF1-CXCR4 axis plays a critical role in promoting angiogenesis and neovascularization, facilitating the formation of a dense network of tumor-associated blood vessels that support the growth and metastatic spread of colon cancer. The interaction between Stromal Cell-Derived Factor 1 (SDF1) and its receptor, C-X-C chemokine receptor type 4 (CXCR4), activates downstream signaling pathways that stimulate the secretion of pro-angiogenic factors, including vascular endothelial

growth factor (VEGF) and basic fibroblast growth factor (bFGF).(44)

SDF1-induced angiogenesis promotes the recruitment and proliferation of endothelial progenitor cells, facilitating the sprouting of new blood vessels from pre-existing vasculature and the establishment of an extensive network of tumor-associated blood vessels. This process enhances nutrient supply and oxygenation within the tumor microenvironment, providing vital support for tumor growth and metastatic colonization.(27)

Moreover, the dysregulated SDF1-CXCR4 signaling network influences the remodeling of the extracellular matrix and the secretion of proteolytic enzymes, facilitating the degradation of basement membranes and the promotion of endothelial cell migration and invasion. These processes contribute to the formation of aberrant, leaky tumor-associated blood vessels that exhibit irregular morphology and enhanced permeability, fostering an environment conducive to intravasation and tumor cell dissemination.(51)

Understanding the pivotal role of the SDF1-CXCR4 axis in angiogenesis and neovascularization provides crucial insights into the mechanisms underlying colon cancer progression, highlighting the potential of targeting this axis as a promising therapeutic approach for modulating tumor angiogenesis and disrupting the tumor microenvironment to improve patient outcomes.(58)

5.3. Metastasis and Invasion

The SDF1-CXCR4 axis serves as a critical modulator of metastasis and invasion in colon cancer, facilitating the dissemination of tumor cells to distant anatomical sites and contributing to the acquisition of an aggressive and invasive phenotype. Dysregulated SDF1-CXCR4 signaling promotes tumor cell invasion through the activation of key downstream effectors, including matrix metalloproteinases (MMPs) and urokinase-type plasminogen activator (uPA), which facilitate the degradation of the extracellular matrix and basement membranes, enabling tumor cells to breach tissue barriers and invade adjacent tissues and blood vessels.(2)

Moreover, the SDF1-CXCR4 axis induces the epithelial-mesenchymal transition (EMT), a critical process that promotes the conversion of epithelial tumor cells into motile and invasive mesenchymal-like cells. Through the activation of EMT-related transcrip-

tion factors, such as Snail, Slug, and Twist, SDF1-CXCR4 signaling fosters the downregulation of epithelial markers (e.g., E-cadherin) and the upregulation of mesenchymal markers (e.g., N-cadherin, vimentin), promoting cellular plasticity and enhancing tumor cell motility and invasiveness.(60)

Furthermore, the SDF1-CXCR4 axis plays a pivotal role in the regulation of metastatic colonization, facilitating the homing of circulating tumor cells to distant organs through the recruitment of CXCR4-expressing cells within the pre-metastatic niche. The interaction between SDF1 and CXCR4 within the target organ microenvironment promotes the adhesion and extravasation of tumor cells, initiating the formation of metastatic foci and facilitating the establishment of secondary tumors.(19)

the intricate mechanisms underlying the role of the SDF1-CXCR4 axis in metastasis and invasion provides valuable insights into the molecular determinants of colon cancer progression, highlighting the potential of targeting this axis as a promising therapeutic strategy for mitigating tumor metastasis and improving patient outcomes.(51)

6. Clinical Correlations: SDF1-CXCR4 Expression and Patient Outcomes

The aberrant expression of the Stromal Cell-Derived Factor 1 (SDF1) and its cognate receptor, C-X-C chemokine receptor type 4 (CXCR4), serves as a potential prognostic biomarker with significant clinical implications for patient outcomes in colon cancer. Elevated levels of CXCR4 expression correlate with advanced disease stages, lymph node metastasis, and distant organ colonization, reflecting a poor prognosis and reduced overall survival rates among colon cancer patients.(1)

Moreover, dysregulated SDF1-CXCR4 signaling is associated with an increased risk of tumor recurrence and treatment resistance, underscoring its significance as a predictive marker for therapeutic response and disease progression. The overexpression of CXCR4 within the tumor microenvironment is indicative of a more aggressive tumor phenotype characterized by enhanced invasion, metastasis, and resistance to conventional chemotherapy and targeted agents.(35)

Clinical studies have demonstrated a direct correlation between high

SDF1-CXCR4 expression levels and adverse clinical outcomes, emphasizing the potential of SDF1-CXCR4 as a promising therapeutic target and prognostic indicator in colon cancer management. Integrating SDF1-CXCR4 expression profiling into clinical practice holds promise for improving risk stratification, guiding treatment decisions, and enhancing patient outcomes through the implementation of tailored therapeutic strategies aimed at mitigating the adverse effects of dysregulated SDF1-CXCR4 signaling.(57)

6.1. Prognostic Significance of SDF1-CXCR4 Axis in Colon Cancer

The dysregulated expression of the Stromal Cell-Derived Factor 1 (SDF1) and its corresponding receptor, C-X-C chemokine receptor type 4 (CXCR4), serves as a valuable prognostic indicator in colon cancer, with implications for disease progression, metastatic spread, and overall patient survival. Elevated levels of CXCR4 expression within the tumor microenvironment are associated with advanced disease stages, lymph node involvement, and distant metastasis, reflecting a poor prognosis and diminished survival outcomes among colon cancer patients.(50)

Clinical investigations have revealed a direct correlation between high SDF1-CXCR4 expression levels and unfavorable clinical prognoses, underscoring the potential of SDF1-CXCR4 as a predictive biomarker for disease recurrence and treatment response. The overexpression of CXCR4 is indicative of an aggressive tumor phenotype characterized by enhanced invasiveness, angiogenic potential, and resistance to conventional therapeutic modalities, highlighting its significance as a promising therapeutic target and prognostic determinant in colon cancer management.(44)

Furthermore, the integration of SDF1-CXCR4 expression profiling into clinical practice offers the potential for improved risk stratification, individualized treatment planning, and the development of targeted therapeutic interventions aimed at disrupting key signaling pathways driving tumor progression and metastasis. Comprehensive evaluation of the prognostic significance of the SDF1-CXCR4 axis provides valuable insights into the molecular determinants of colon cancer aggressiveness, guiding the implementation of tailored treatment strategies to improve patient outcomes and enhance

overall survival rates.(60)

6.2. Therapeutic Implications and Targeted Interventions

The disregulated SDF1-CXCR4 axis represents a promising therapeutic target in the management of colon cancer, with implications for the development of innovative targeted interventions aimed at mitigating tumor progression and improving patient outcomes. Targeting the SDF1-CXCR4 axis through various pharmacological agents, including small-molecule inhibitors, monoclonal antibodies, and CXCR4 antagonists, offers a potential strategy for disrupting key signaling pathways driving tumor growth, metastasis, and therapeutic resistance.(59)

Preclinical studies have demonstrated the efficacy of CXCR4 antagonists in attenuating tumor cell invasion, suppressing metastatic spread, and sensitizing tumor cells to conventional chemotherapy and targeted therapies. The inhibition of CXCR4-mediated signaling cascades impedes tumor cell proliferation, survival, and angiogenesis, highlighting the therapeutic potential of targeting CXCR4 as an adjuvant approach to standard treatment regimens.(12)

Moreover, the integration of SDF1-CXCR4-targeted therapies into personalized treatment strategies holds promise for improving treatment efficacy and enhancing patient outcomes through the development of tailored therapeutic interventions that address the specific molecular alterations driving tumor progression and metastasis. The identification of predictive biomarkers and the implementation of precision medicine approaches enable the stratification of patient populations, facilitating the selection of optimal treatment regimens and the customization of therapeutic interventions based on individual tumor profiles.(51)

The therapeutic implications of the SDF1-CXCR4 axis provides valuable insights into the development of novel targeted interventions and the advancement of precision oncology approaches, underscoring the potential of SDF1-CXCR4 as a promising therapeutic target for the effective management of colon cancer.(52).

7. Interplay with Other Molecular Pathways

The SDF1-CXCR4 axis interacts dynamically with various other molecular pathways within the complex landscape of colon cancer, contribut-

ing to the modulation of key signaling cascades that regulate tumor growth, metastasis, and immune evasion. The interplay between the SDF1-CXCR4 axis and oncogenic signaling pathways, such as the KRAS and BRAF pathways, influences the acquisition of an aggressive tumor phenotype characterized by enhanced cell proliferation, survival, and resistance to targeted therapies.(53)

Moreover, the crosstalk between the SDF1-CXCR4 axis and the tumor suppressor p53 pathway regulates the balance between cell cycle progression and apoptosis, impacting the susceptibility of tumor cells to apoptotic stimuli and DNA damage. Dysregulated SDF1-CXCR4 signaling modulates the activity of p53 and its downstream effectors, influencing the apoptotic response and contributing to therapeutic resistance in colon cancer.(33)

Furthermore, the interplay between the SDF1-CXCR4 axis and immune regulatory pathways, such as the PD-1/PD-L1 pathway, shapes the immunosuppressive tumor microenvironment and influences the efficacy of immunotherapy. The recruitment of immunosuppressive cell populations by the SDF1-CXCR4 axis contributes to immune evasion and immune checkpoint activation, promoting tumor immune escape and resistance to immune-mediated cytotoxicity.(54)

The intricate interplay between the SDF1-CXCR4 axis and other molecular pathways provides valuable insights into the multifaceted mechanisms underlying colon cancer pathogenesis, highlighting the potential of combination therapies targeting multiple signaling nodes to effectively disrupt tumor growth, metastasis, and therapeutic resistance, and improve patient outcomes.(55).

7.1 Crosstalk with Oncogenic Signaling (e.g., KRAS, BRAF)

The SDF1-CXCR4 axis interacts intricately with oncogenic signaling pathways, including KRAS and BRAF, in the context of colon cancer, contributing to the modulation of critical cellular processes associated with tumor growth and progression. Disregulated KRAS and BRAF signaling is frequently observed in colon cancer and has been linked to increased SDF1-CXCR4 expression levels, promoting tumor cell proliferation, survival, and metastatic dissemination.(56)

Studies have demonstrated that the aberrant activation of the KRAS and

BRAF pathways upregulates the expression of SDF1 and CXCR4, fostering a pro-tumorigenic microenvironment that supports tumor growth and metastasis. Additionally, the crosstalk between the SDF1-CXCR4 axis and KRAS/BRAF signaling influences the acquisition of aggressive phenotypes and treatment resistance in colon cancer, further complicating the management of advanced-stage disease.(27)

The intricate interplay between the SDF1-CXCR4 axis and oncogenic KRAS and BRAF signaling is vital for elucidating the underlying mechanisms of colon cancer pathogenesis and for the development of integrated therapeutic strategies that effectively target multiple signaling nodes to improve treatment outcomes.(57)

7.2 Influence on Immune Response and Tumor Microenvironment

The SDF1-CXCR4 axis plays a significant role in modulating the immune response and shaping the tumor microenvironment in colon cancer. Through its interactions with immune cells, including T cells, natural killer cells, and myeloid-derived suppressor cells, the SDF1-CXCR4 axis influences immune cell recruitment, trafficking, and function within the tumor milieu.(16)

Studies have highlighted the impact of SDF1-CXCR4 signaling on the polarization of immune cells towards a pro-tumorigenic phenotype, leading to the suppression of anti-tumor immune responses and the establishment of an immunosuppressive microenvironment. Additionally, the SDF1-CXCR4 axis is implicated in the recruitment of regulatory T cells and tumor-associated macrophages, promoting immune evasion and facilitating tumor immune escape mechanisms.(29)

The influence of the SDF1-CXCR4 axis on the immune response and tumor microenvironment is crucial for devising immunomodulatory strategies and combination therapies that target both the tumor cells and the immune cells, thus promoting anti-tumor immunity and improving treatment outcomes in colon cancer.(59).

8. Translational Approaches and Clinical Trials

Translational research focused on the SDF1-CXCR4 axis in colon cancer has paved the way for the development of innovative therapeutic strategies and the initiation of clinical trials aimed at evaluating the efficacy and

safety of targeted interventions. Various translational approaches, including the identification of biomarkers associated with SDF1-CXCR4 expression and the validation of preclinical models, have facilitated the translation of basic research findings into clinical applications.(60)

Clinical trials investigating the therapeutic potential of SDF1-CXCR4-targeted agents, such as small-molecule inhibitors and monoclonal antibodies, have demonstrated promising results in terms of their ability to inhibit tumor progression, suppress metastatic spread, and enhance treatment responses in colon cancer patients. These trials have provided valuable insights into the safety profiles, pharmacokinetics, and pharmacodynamics of SDF1-CXCR4-targeted therapies, laying the groundwork for their integration into standard-of-care treatment regimens.(18)

The implications of translational research and clinical trials targeting the SDF1-CXCR4 axis is essential for advancing precision medicine approaches and improving clinical outcomes in patients with colon cancer.(12)

8.1 Biomarker Potential of SDF1-CXCR4 Axis in Colon Cancer

The SDF1-CXCR4 axis exhibits significant biomarker potential in colon cancer, with implications for risk stratification, disease monitoring, and treatment response assessment. Various studies have highlighted the utility of SDF1 and CXCR4 as prognostic biomarkers for predicting tumor aggressiveness, metastatic potential, and overall survival outcomes in colon cancer patients.(14)

Additionally, the expression levels of SDF1 and CXCR4 have shown promise as predictive biomarkers for treatment response to SDF1-CXCR4-targeted therapies and conventional chemotherapeutic regimens. The assessment of SDF1-CXCR4 expression in primary tumor tissues and circulating tumor cells has provided valuable insights into disease progression and therapeutic resistance, facilitating the development of personalized treatment strategies and the monitoring of treatment efficacy in real time.(24)

The biomarker potential of the SDF1-CXCR4 axis is crucial for the implementation of precision medicine approaches that leverage biomarker-guided decision-making to optimize

treatment outcomes and improve patient survival in colon cancer.(18)

8.2 Clinical Trials Investigating SDF1-CXCR4 Targeted Therapies

Clinical trials focusing on SDF1-CXCR4 targeted therapies have demonstrated promising results in the management of colon cancer, offering insights into the safety, efficacy, and clinical utility of targeted interventions aimed at disrupting the SDF1-CXCR4 axis. These trials have evaluated various SDF1-CXCR4 inhibitors, monoclonal antibodies, and immune-based therapies in both the adjuvant and metastatic settings, providing valuable data on their therapeutic potential and their impact on patient outcomes.(20)

Preliminary findings from these clinical trials have shown that SDF1-CXCR4 targeted therapies exhibit favorable safety profiles and demonstrate encouraging anti-tumor activity, including the inhibition of tumor growth, the suppression of metastatic spread, and the improvement of treatment responses in colon cancer patients. Moreover, the combination of SDF1-CXCR4 inhibitors with standard-of-care chemotherapeutic agents has shown synergistic effects, emphasizing the potential for enhanced therapeutic efficacy and improved survival rates.(25)

The implications of clinical trials investigating SDF1-CXCR4 targeted therapies is essential for accelerating the development of novel treatment strategies and for advancing precision medicine approaches in colon cancer management.(2).

9. Personalized Medicine and Future Directions

The emerging field of personalized medicine holds great promise for the tailored management of colon cancer, with a specific focus on targeting the SDF1-CXCR4 axis. Personalized medicine approaches encompass the integration of molecular profiling, biomarker-guided decision-making, and individualized treatment strategies that leverage the unique molecular characteristics of each patient's tumor.(7)

Future directions in personalized medicine for colon cancer may involve the development of novel therapeutic modalities, including genetically engineered cell therapies, immunomodulatory agents, and combination treatment regimens that target both the tumor cells and the tumor microenvironment. Additionally, the incorporation of ad-

vanced imaging techniques and liquid biopsy-based assays for the real-time monitoring of treatment responses and disease progression is poised to revolutionize clinical practice and improve patient outcomes.(33)

The potential of personalized medicine and its future applications in targeting the SDF1-CXCR4 axis is instrumental in advancing precision oncology and in establishing a paradigm shift towards more effective, patient-centered approaches to colon cancer treatment.(9)

9.1 Patient Stratification for SDF1-CXCR4 Targeted Therapies

The effective stratification of patients for SDF1-CXCR4 targeted therapies is crucial for optimizing treatment outcomes and maximizing the clinical benefits of targeted interventions in colon cancer. Various approaches for patient stratification, including the assessment of SDF1-CXCR4 expression levels, the profiling of tumor molecular subtypes, and the identification of predictive biomarkers, enable the selection of patients who are most likely to benefit from SDF1-CXCR4 targeted therapies.(10)

Integration of multi-omics data, such as genomics, transcriptomics, and proteomics, with advanced imaging techniques and liquid biopsy-based assays, facilitates comprehensive patient stratification and the identification of molecular signatures associated with SDF1-CXCR4-mediated tumor progression and metastasis. Moreover, the development of predictive models and risk assessment tools based on these stratification approaches aids in the customization of treatment regimens and the implementation of personalized therapeutic strategies tailored to each patient's unique disease profile.(17)

The significance of patient stratification for SDF1-CXCR4 targeted therapies is essential for advancing precision oncology and for ensuring the optimal allocation of resources to patients who are most likely to benefit from these targeted interventions.(44)

9.2 Emerging Strategies and Technological Advancements

The ever-evolving landscape of cancer research has led to the emergence of innovative strategies and technological advancements aimed at unraveling the complexities of the SDF1-CXCR4 axis in colon cancer. Recent advances in single-cell sequencing technologies, spatial transcriptomics, and multi-parametric

imaging modalities have enabled the comprehensive characterization of the tumor microenvironment and the dynamic interactions between tumor cells and the immune system.(15)

Moreover, the development of advanced gene editing tools, such as CRISPR-Cas9, and the application of high-throughput drug screening platforms have facilitated the identification of novel therapeutic targets and the discovery of potential combination treatment regimens that effectively target the SDF1-CXCR4 axis and associated signaling pathways.(6)

The integration of these emerging strategies and technological advancements holds great promise for advancing our understanding of the molecular mechanisms underlying colon cancer progression and for accelerating the development of precision therapies that target the SDF1-CXCR4 axis, thus improving treatment efficacy and patien1t outcomes.(27)

9.3 Significance of the SDF1-CXCR4 Axis in Colon Cancer Management

The SDF1-CXCR4 axis holds significant clinical and therapeutic implications in the comprehensive management of colon cancer. Its multifaceted roles in mediating tumor growth, metastasis, and immune evasion have positioned it as a critical biomarker and therapeutic target in the development of precision medicine approaches for colon cancer patients. By serving as a key mediator of tumor progression and metastatic spread, the SDF1-CXCR4 axis offers valuable insights into disease aggressiveness and treatment response, enabling the stratification of patients based on their molecular profiles and the customization of targeted treatment regimens tailored to individual disease characteristics.(33)

Furthermore, the significance of the SDF1-CXCR4 axis extends beyond its prognostic value, as it also represents a promising therapeutic target for the development of novel treatment modalities that aim to disrupt tumor-promoting signaling pathways and enhance the efficacy of conventional chemotherapeutic agents. The integration of SDF1-CXCR4-targeted therapies into standard-of-care treatment regimens has shown promise in preclinical and clinical settings, demonstrating favorable safety profiles and encouraging anti-tumor activity, thus underscoring its potential as a viable therapeutic avenue for improving patient outcomes

and prolonging survival rates.(28)

The significance of the SDF1-CXCR4 axis in colon cancer management is pivotal for advancing the field of precision oncology and for fostering the development of tailored treatment strategies that maximize therapeutic benefits while minimizing potential adverse effects, ultimately improving the overall quality of life for individuals affected by this disease.(18)

9.4 Towards Enhanced Therapeutic Strategies and Patient Outcomes

Advancements in the understanding of the SDF1-CXCR4 axis have paved the way for the development of enhanced therapeutic strategies aimed at improving patient outcomes in colon cancer management. Novel therapeutic interventions targeting the SDF1-CXCR4 axis, including monoclonal antibodies, small-molecule inhibitors, and immune-based therapies, have demonstrated promising results in preclinical and clinical settings, highlighting their potential as effective treatment modalities for combating tumor progression and metastasis.(22)

Furthermore, the integration of combination therapies that simultaneously target the SDF1-CXCR4 axis and other key signaling pathways implicated in colon cancer pathogenesis holds promise for achieving synergistic treatment effects and overcoming therapeutic resistance. By leveraging the insights gained from these advanced therapeutic strategies, the field is poised to deliver more precise and personalized care that maximizes treatment efficacy and minimizes the adverse effects associated with traditional chemotherapy and radiation therapy.(1)

Moreover, the implementation of comprehensive patient-centric approaches, integrating biomarker-guided patient stratification and real-time monitoring of treatment responses, is anticipated to further improve clinical decision-making and optimize treatment regimens tailored to the unique molecular profiles of individual patients. By tailoring treatment strategies to the specific needs of each patient, the field is positioned to enhance overall patient outcomes, prolong survival rates, and ultimately improve the quality of life for individuals affected by colon cancer.(15)

The advancements in therapeutic strategies and their impact on patient outcomes is crucial for fostering a paradigm shift in colon cancer management, where precision medicine

approaches become the cornerstone of modern oncology practice, ultimately leading to more effective and individualized care for patients worldwide.(22)

10. Conclusion

The research underscores the SDF1-CXCR4 axis as a significant target for therapy and prognosis in colon cancer, highlighting its role in cancer's fundamental characteristics and treatment resistance. The success of therapies targeting this axis offers hope for enhancing patient outcomes. Advances in personalized medicine, particularly treatments tailored to target the SDF1-CXCR4 axis and related pathways, promise more accurate and individualized care for colon cancer patients. Future efforts should focus on uncovering the complex molecular interactions involving the SDF1-CXCR4 axis to develop more effective treatments, moving towards personalized care that improves survival and quality of life for colon cancer patients.

References:

1. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683-691.
2. Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet. 2019;394(10207):1467-1480.
3. Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065
.4 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767.
5. Dienstmann R, Salazar R, Tabernero J. Molecular subtypes and the evolution of treatment decisions in metastatic colorectal cancer. Am Soc Clin Oncol Educ Book. 2018;38:231-238.
6. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449-2460.
7. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50-56.
8. Teicher BA, Fricker SP. CXCL12

(SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927-2931.

9. Liang Z, Brooks J, Willard M, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun. 2007;359(3):716-722.
10. Nagasawa T. CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4 in the regulation of hematopoiesis and immune responses. Arch Immunol Ther Exp (Warsz). 2006;54(2):75-94.
11. Ara T, Tokoyoda K, Sugiyama T. SDF-1/CXCL12: A chemokine in the life cycle of a B cell. Immunol Rev. 2012; 247(1): 158-166.
12. Ding BS, Nolan DJ, Guo P, et al. Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell. 2011;147(3):539-553.
13. Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta. 2007;1768(4):952-963.
14. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927-2931.
15. Bachelerie F, Ben-Baruch A, Burkhardt AM, et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2014;66(1):1-79.
16. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11(9):597-606.
17. Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer. 2013;49(1):219-230.
18. Liang Z, Yoon Y, Votaw J, et al. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005;65(3):967-971.
19. Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer. 2013;49(1):219-230.
20. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540-550.
21. Liang Z, Yoon Y, Votaw J, et al. Silencing of CXCR4 blocks breast

cancer metastasis. Cancer Res. 2005;65(3):967-971.
22. Chen W, Du J, Wu J, et al. Stromal cell-derived factor 1/CXCR4 signaling modifies the tumor-associated immune status of colorectal cancer. Oncol Lett. 2019;18(3): 3263–3270.
23. Kryczek I, Wei S, Keller E, et al. Stroma-derived factor (SDF-1/ CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol. 2007;292(3):C987-C995.
24. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335-348.
25. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50-56.
26. Liang Z, Brooks J, Willard M, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun. 2007;359(3):716-722.
27. Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer. 2013;49(1):219-230.
28. De la Roche M, Asano Y, Griffiths GM. Origins of the cytolytic synapse. Nat Rev Immunol. 2016;16(7):421-432.
29. Siveen KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta. 2014;1845(2):136-154.
30. Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer. 2013;49(1):219-230.
31. Liang Z, Brooks J, Willard M, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun. 2007;359(3):716-722.
32. De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med. 2012;44(1):1-9.
33. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-257.
34. Sun Y, Cheng Z, Ma L, Pei G. Be-

ta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem. 2002;277(51):49212-49219.

35. De la Roche M, Asano Y, Griffiths GM. Origins of the cytolytic synapse. Nat Rev Immunol. 2016;16(7):421-432.
36. Chong Y, Tang D, Xiong Q, Jiang X. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell Int. 2014;14:70.
37. Duda DG, Kozin SV, Kirkpatrick ND, et al. CXCL12 (SDF1α)-CXCR4/CXCR7 pathway inhibition: An emerging sensitizer for anticancer therapies? Clin Cancer Res. 2011;17(8):2074-2080.
38. Sehgal A, Keener C, Boynton AL, Warrick J. Murphy G. The role of the CXCL12-CXCR4 axis in the metastatic behavior of HER2+ breast cancer cells: An in vitro and in vivo study. Anticancer Res. 2014;34(1): 364-374.
39. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540-550.
40. Liang Z, Yoon Y, Votaw J, et al. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005;65(3):967-971.
41. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927-2931.
42. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11(9):597-606.
43. Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31-82.
44. Sun Y, Cheng Z, Ma L, Pei G. Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem. 2002;277(51):49212-49219.
45. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927-2931
46. Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177-182.
47. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase func-

tion is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem. 2000;275(47):36803-36810.

48. Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31-82.
49. Yaeger R, Cowell E, Chou JF, et al. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 2015;121(8):1195-1203.
50. Kahlert C, Lahes S, Radhakrishnan P, et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res. 2011;17(24):7654-7663.
51. Al-Assaf, A. I., Ali, H. M., & Ad'hiah, A. H. (2021). Gene Expression of NLRP3 Inflammasome in Celiac Disease of Iraqi Children. Ibn AL-Haitham Journal For Pure and Applied Sciences, 2021, 15-22.
52. Musawi, I. H. N. A., Mahood, W. S., Jawad, M. M., & Jawad, A. A. (2017). Detection of BRAF Gene in Some Iraqi Bowel Inflammation and Colorectal Cancer Patients. Ibn AL-Haitham Journal For Pure and Applied Sciences, 30(1), 1-10.
53. Al-Saigh, T. H., Al-Bayati, S. A., Abdulmawjood, S. A., & Ahmed, F. A. (2019). Descriptive study of colorectal cancer in iraq, 1999-2016. Annals of the College of Medicine, Mosul, 41(1), 81-85.
54. Iqbal, M. N., Merdas, A. H., & Hussein, M. A. (2014). ROLE OF IMMUNOLOGICAL MARKERS IN CERTAIN GASTROENTEROLOGICAL DISORDERS. Journal of Techniques, 27(2).
55. Hameed, H. A., Naser, A. Y., & Talib, N. M. (2022). Clinical and therapeutic characteristics and medical cost of managing cancer patients in Al-Anbar, Iraq: A cross-sectional study. Saudi Pharmaceutical Journal, 30(12), 1802-1808.
56. Jaloud, R. E., & Hassan, F. F. (2009). Isolation and Identification of Fungal Propagation in Iraqi Meat and Detection of Aflatoxin B1 Using ELISA Technique.
57. Ridha, H. S., & Kadri, Z. H. (2018). Assessment of some immunological biomarkers in saliva and serum of Iraqi patients with chronic periodontitis disease. Journal of Phar-

maceutical Sciences and Research, 10(11), 2998-3000.

58. AL-Eqabi, H. F. K., Abd AL, S. A. A. H., & ALabassi, H. M. (2022). Dynamic role of IL-33, ST2 axis, SOD, leptin and nitric oxide in pathogenicity and disease progression in HBV chronic infection in Iraqi patients. Journal of Pharmaceutical Negative Results, 13(4), 258-263.
59. Ismael, A. K., & Alabassi, H. M. (2023). PD-1 and NFATc1 as promising immunotherapy for SLE patients. *Journal of Population Therapeutics and Clinical Pharmacology*, *30*(5), 260-266.
60. 60.Rasheed, R. A., & Al-Abassi, H. M. (2022). IL-17 (gene expression) as a new biological marker for diagnosing the gastric and colorectal cancer. International Journal of Health Sciences, 6(S8), 103–111.